Advances on Tumor-Targeting Delivery of Cytotoxic Proteins

Area of Science:

• Biochemistry
• Molecular Biology
• Nanotechnology

Background:

• Cytotoxic proteins, such as ribosome-inactivating proteins (RIPs), exhibit potent anticancer activity.
• Their large size prevents efflux by multidrug resistance transporters, a common issue with small molecule drugs.
• However, significant biobarriers impede the effective delivery of these proteins to tumor sites for clinical application.

Purpose of the Study:

• To review two representative type I RIPs: trichosanthin (TCS) and gelonin (Gel).
• To provide an overview of the major biobarriers encountered in protein-based cancer therapy.
• To outline recent advancements in smart drug delivery systems (DDS) designed to overcome these barriers for enhanced protein delivery in cancer treatment.

Main Methods:

• Literature review focusing on cytotoxic proteins (RIPs) and their anticancer mechanisms.
• Analysis of biobarriers affecting protein drug delivery in cancer therapy.
• Survey of smart drug delivery systems (DDS) engineered for protein therapeutics.

Main Results:

• Identified cytotoxic proteins like TCS and Gel as promising anticancer agents due to cellular retention.
• Characterized key biobarriers including immunogenicity, degradation, and poor tumor penetration.
• Highlighted the potential of smart DDS to improve the stability, targeting, and efficacy of protein-based cancer therapies.

Conclusions:

• Smart drug delivery systems offer a viable strategy to overcome the limitations of protein-based cancer therapeutics.
• Effective delivery of cytotoxic proteins like trichosanthin and gelonin can be achieved through advanced DDS.
• Further development of these systems holds significant promise for improving cancer treatment outcomes.